Saturday 17 October 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
16.49
0.83
−4.79%
Follow JANX
Janux Therapeutics, Inc. (JANX) P/E ratio
Janux Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMTX Immatics N.V. compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| JANX Janux Therapeutics, Inc. | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| MNKD MannKind Corporation compare | n/m |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SVRA Savara Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)